Загрузка...
How Generalizable Are Cardiovascular Outcome Trials of Sodium-Glucose Co-Transporter-2 Inhibitors? A National Database Study: Study Protocol
INTRODUCTION: Sodium-glucose co-transporter-2 (SGLT2) inhibitors are oral antihyperglycemic agents for the treatment of people with type 2 diabetes (T2DM). Two recent cardiovascular outcome trials (CVOTs), the EMPA-REG OUTCOME trial and CANVAS Program, have demonstrated that SGLT2 inhibitors have ca...
Сохранить в:
| Опубликовано в: : | Diabetes Ther |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer Healthcare
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6531500/ https://ncbi.nlm.nih.gov/pubmed/31041781 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-019-0620-8 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|